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Abstract
Introduction: Rheumatoid arthritis (RA) is characterized by progressive inflammation associated with rampantly
proliferating synoviocytes and joint destruction due to oxidative stress. Recently, we described nuclear factor
erythroid 2-related factor 2 (Nrf2) as a major requirement for limiting cartilage destruction. NF-B and AP-1 are the
main transcription factors triggering the inflammatory progression in RA. We used sulforaphane, an isothiocyanate,
which is both an Nrf2 inducer and a NF-B and AP-1 inhibitor.
Methods: Cultured synoviocytes were stimulated with sulforaphane (SFN) with or without TNF-a pre-treatment.
NF-B, AP-1, and Nrf2 activation was investigated via dual luciferase reporter gene assays. Matrix metalloproteinases
(MMPs) were measured via zymography and luminex technique. Cytokine levels were detected using ELISA. Cell
viability, apoptosis and caspase activity were studied. Cell proliferation was analysed by real-time cell analysis.
Results: SFN treatment decreased inflammation and proliferation dose-dependently in TNF-a-stimulated
synoviocytes. SFN did not reduce MMP-3 and MMP-9 activity or expression significantly. Interestingly, we
demonstrated that SFN has opposing effects on naïve and TNF-a-stimulated synoviocytes. In naïve cells, SFN
activated the cytoprotective transcription factor Nrf2. In marked contrast to this, SFN induced apoptosis in TNF-a-
pre-stimulated synoviocytes.
Conclusions: We were able to show that SFN treatment acts contrary on naïve and inflammatory synoviocytes.
SFN induces the cytoprotective transcription factor Nrf2 in naïve synoviocytes, whereas it induces apoptosis in
inflamed synoviocytes. These findings indicate that the use of sulforaphane might be considered as an adjunctive
therapeutic strategy to combat inflammation, pannus formation, and cartilage destruction in RA.
Introduction
Rheumatoid arthritis (RA) is an inflammatory autoim-
mune disease, in which the proinflammatory transcrip-
tion factors nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-B) and activator protein-1 (AP-1)
are activated by inflammatory cytokines, which in turn
upregulate the expression of these cytokines, thereby
assembling a positive feedback loop perpetuating inflam-
mation [1,2]. Moreover, TNF-a induces cell proliferation
in synovial cells and triggers the generation of pannus
tissue [3,4].
Searching for agents that are potentially beneficial in RA,
we tested sulforaphane (SFN) in an in vitro model of RA.
SFN is known as a potent inducer of the transcription fac-
tor nuclear factor erythroid 2-related factor 2 (Nrf2),
which upregulates a battery of protective enzymes [5].
Moreover, it has been shown that SFN suppresses prolif-
eration and induces apoptosis in various cancer cells [6].
Recently, we provided strong evidence that oxidative stress
is significantly involved in cartilage degradation in experi-
mental arthritis, indicating that Nrf2 activation is a major
requirement for limiting cartilage destruction [7,8]. Hinoi
et al. provided first evidence that Nrf2 is a negative regula-
tor of chondrocyte differentiation during embryogenesis
and postnatal development [9]. On the other hand, Nrf2
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seemed to protect differentiated chondrocytes in a mouse
model of RA [8].
In the present study, we used the human synoviocyte
cell lines HSE and K4IM, which were stimulated with
TNF-a to mimic a state of inflammation. We were able
to show that SFN selectively induces apoptosis in TNF-
a pre-stimulated but not in unstimulated synoviocytes.
In addition, SFN stimulates Nrf2 activity and renders
unstimulated synoviocytes against oxidative stress.
These findings indicate that treatment of RA patients
with SFN might inhibit inflammation and pannus for-
mation while preserving healthy tissue.
Materials and methods
Material
RPMI 1640 medium with 2 mM glutamine was obtained
from PAA Laboratories, Pasching, Austria. Sulforaphane
(SFN) was obtained from Sigma-Aldrich Chemical Com-
pany, Munich, Germany. All other chemicals were of
the highest quality commercially available.
Cell culture
The human synoviocyte cell line HSE was obtained
from Oligene, Berlin, Germany. These cells were pro-
duced by immortalisation of primary human synovial
fibroblasts from a confirmed RA patient. Immortalisa-
tion was performed using a pGEM vector containing a
SV40 Tag-encoding DNA fragment [10]. The immorta-
lised human synoviocyte cell line K4IM was a generous
gift from Christian Kaps (Charité, Berlin, Germany).
These cells originate from synovial tissue of a 41-year-
old male donor suffering from a meniscus lesion and
were also immortalised by a pGEM7/SV40 TAg vector
construct. Several studies confirmed that both immor-
talised cell lines represent a valuable tool to study
mechanisms that induce synoviocyte activation [11-13].
Both cell lines were cultured as monolayers in RPMI
1640 medium supplemented with 10% (v/v) foetal calf
serum (FCS), 2 mM glutamine and 50 μg/mL penicil-
lin-streptomycin.
Stimulation protocols
We used K4IM cells for the analysis of the inflammatory
response of synoviocytes (Figures 1 and 2). The exami-
nation of matrix metalloproteinase (MMP) expression
and activity was conducted with HSE cells (Figure 3),
because it is known that these cells express MMP-3 and
-9. For these experiments, cells were pre-treated for 30
min with solvent or increasing concentrations of SFN,
before they were stimulated with 10 ng/mL TNF-a to
examine the inhibitory effect of SFN on NF-B, AP-1
and the downstream cytokine and MMP expression.
For experiments, which were performed to gain
insights on the effects of SFN on already inflamed cells,
the HSE cell line was used (Figures 4 and 5). These cells
were pre-treated with 10 ng/mL TNF-a for 3 h to
induce a proinflammatory state, before they were stimu-
lated with 6.25 μM SFN for a further 6 h.
Figure 1 Sulforaphane (SFN) inhibits TNF-a-induced activation of NF-B and AP-1. Synoviocytes (K4IM) were pre-treated (30 min) with
increasing concentrations of SFN or solvent and stimulated with 10 ng/mL TNF-a for 6 h. Cells were transfected with p(NF-B)3 (A) or p(AP-1)5
(B) and dual luciferase assay was measured as described in Wruck et al. 2007. Treatment groups were normalised to the control group (= 1). All
experiments were performed with n = 8. Data represent mean + SEM. Statistical significance is marked as ***P < 0.001. (One-way ANOVA with
Bonferroni multiple comparison post hoc test, GraphPad Prism 5 software; GraphPad Software, La Jolla, CA, USA.).
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Transient transfection of cell lines
For transient co-transfection with reporter gene plasmids
together with the Renilla luciferase coding phRL-TK inter-
nal control plasmid, 4.0 × 106 cells were seeded in a 100
mm dish one day before transfection. Transfection was
carried out with Lipofectamine™ 2000 reagent (Invitrogen,
Darmstadt, Germany) according to the manufacturer’s
recommendations. After removal of the transfection mix-
ture, cells were trypsinised and 2.5 × 104 cells per well
were seeded in a 96-well microtitre plate for stimulation
experiments.
Stable Keap1 knockdown via lentiviral short hairpin RNA
(shRNA) transduction
The real-time cell proliferation analysis (RTCA) experi-
ment was performed with HSE cells, which were trans-
duced with a pLKO.1 shRNA construct directed against
Keap1 (MISSION™ shRNA assortment, Sigma-Aldrich,
Germany) by lentiviral gene delivery. In order to exclude
variations due to the vector backbone and to prove that
observed effects are exclusively dependent on the shRNA,
we also transduced HSE cells with a shNonTarget control
construct.
Luciferase assays
After stimulation, cells were lysed in passive lysis buffer
(Promega, Madison, WI, USA) and lysates were trans-
ferred to a white 96-well microtitre plate for luminescence
measurement in a GloMax™ luminometer (Promega,
Madison, WI, USA). Dual-luciferase reporter gene assay
(Promega, Madison, WI, USA) was performed as
described in Wruck et al. 2007. The following constructs
were used:
p(NF-B)3-Luc refers to a concatenated trimer of the
wild-type sequence ATGTGGGATTTTCCCATG (the
core sequence is bold). Both strands:
5’-CATGTGGGATTTTCCCATGAGTGAGGGGAC
TTTCCCAGGCATGTGGGATTTTCCCATGG-3’ and
5’-CTAGCCATGGGAAAATCCCACATGCCTGG-
GAAAGTCCCCTCACTCATGGGAAAATCCCA-
CATGGTAC-3’.
pAP-15-Luc refers to a concatenated pentamer of the
AP-1 consensus sequence TGAGTCA.
pGL3-ARE refers to the antioxidant response element
(ARE) consensus sequence of the rat NAD(P)H dehy-
drogenase, quinone 1 (NQO1) promoter region, as
described in [14].
All strands were cloned in the pGL3-promoter vector
(Promega, Madison, WI, USA). The luciferase assay was
carried out as described in [15].
Enzyme-linked immunosorbent assay (ELISA)
The concentrations of IL-1b and IL-6 in the synoviocyte
culture supernatants were determined by ELISA. The
assay was performed according to the manufacturer’s
instructions.
Figure 2 Sulforaphane (SFN) inhibits TNF-a-induced production of IL-1b and IL-6. Synoviocytes (K4IM) were pre-treated (30 min) with
increasing concentrations of SFN and stimulated with 10 ng/mL TNF-a for 6 h. ELISA for IL-1b (A) and IL-6 (B) was measured as described in
methods. Experiments were performed with n = 8. Graphs represent mean + SEM. Statistical significances are marked as *P < 0.05 vs. control, #P
< 0.05 vs. TNF-a treated only. (One-way ANOVA with Bonferroni multiple comparison post hoc test, GraphPad Prism 5 software; GraphPad
Software, La Jolla, CA, USA.).
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Figure 3 Sulforaphane (SFN) downregulates neither matrix metalloproteinase (MMP) secretion nor catalytic activity. Synoviocytes (HSE)
were pre-treated 30 min with various concentrations of SFN and then stimulated with 10 ng/mL TNF-a for 6 h. Luminex multiplex assay for
MMP-3 (A) and MMP-9 secretion level (B) was carried out as described above. The catalytic activity of MMP-9 was visualised by zymography (C)
and quantified by densitometric analysis with ImageJ (D). All experiments were performed with n = 3. Graphs represent mean + SEM. Statistical
significance is marked as *P < 0.05. (One-way ANOVA with Bonferroni multiple comparison post hoc test, GraphPad Prism 5 software; GraphPad
Software. La Jolla, CA, USA.).
Figure 4 Sulforaphane (SFN) induces apoptosis in TNF-a pre-treated ‘transformed’ synoviocytes. HSE wild-type cells were either pre-
treated (3 h) with 10 ng/mL TNF-a and then stimulated for a further 6 h with 6.25 μM SFN or only stimulated for 6 h with 6.25 μM SFN without
TNF-a pre-treatment and WST (A), CytoTox-Glo™ (B) and Caspase-Glo™ 3/7 (C) assays were performed as recommended by the manufacturers.
All experiments were performed with n = 8. Graphs represent mean + SEM. Statistical significances are indicated as *P < 0.05, **P < 0.01, ***P <
0.001. (One-way ANOVA with Bonferroni multiple comparison post hoc test, GraphPad Prism 5 software; GraphPad Software, La Jolla, CA, USA.).
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Luminex xMAP™ multiplex assay
The total levels of secreted MMP-3 and MMP-9 were
quantified by Luminex xMAP™ technology in duplicates.
For that purpose, HSE culture supernatants were used
after experimental treatment. The Fluorokine™ MAP
human MMP base kit (Catalogue No. LMP000) was pur-
chased from R&D Systems (Minneapolis, MN, USA) and
utilised as recommended by the manufacturer.
Zymographic analysis
Zymographic analysis was used to determine the activity
of MMP-9 after secretion into the cell culture medium
over a fixed period of time. The method was performed
according to a standard procedure described previously
[16]. Briefly, following 24 h of experimental treatment,
cell-conditioned media were harvested and concentrated
for zymography. Total protein concentrations were
Figure 5 Nrf2 activation leads to decreased proliferation of TNF-a pre-treated synoviocytes. HSE cells were co-transfected with pGL3-ARE/
phRL-TK and either pre-treated (3 h) with 10 ng/mL TNF-a and then stimulated for a further 6 h with 6.25 μM sulforaphane (SFN) or only
stimulated for 6 h with 6.25 μM SFN without TNF-a pre-treatment. Afterwards, dual luciferase reporter gene (DLR) assay was carried out (A-C). A
real-time cell analysis (RTCA) experiment was performed with HSE cells stably transduced with either a shRNA targeting Keap1 mRNA or a
shNonTarget control construct. Twenty-four h after seeding, the cells were treated with 10 ng/mL TNF-a and were observed for further 24 h by
the RTCA device (D). The Cell Index was determined at three time-points (TP) (E) and the slope of the curve was calculated for three
characteristic phases of proliferation (F). All experiments were performed with n = 8. Graphs represent mean + SD. Statistical significances are
indicated as $P < 0.05, $$P < 0.01, $$$P < 0.001 vs. control; ###P < 0.001 vs. all other groups; *P < 0.05, **P < 0.01, ***P < 0.001 as indicated.
(DLR: one-way ANOVA with Bonferroni multiple comparison post hoc test; RTCA analysis: two-way ANOVA with Bonferroni post hoc tests,
GraphPad Prism 5 software; GraphPad Software, La Jolla, CA, USA.).
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determined by BCA (bicinchoninic acid) protein assay.
Equal concentrations of total protein were used for analy-
sis. Therefore, a total sample volume of 15 μL was loaded
on a 12.5% PAGE gel containing 0.1% gelatin (BioRad,
Munich, Germany). Gels were run for 90 min at 150
volts and were then incubated in 2.5% Triton-X (Merck,
Darmstadt, Germany) for 1 h at room temperature (RT)
on a rocker. In the next step, they were washed with dis-
tilled water and incubated overnight in renaturation buf-
fer (10 mM Tris HCl, 1 mM CaCl2 × 2 H2O, 40 mM
NaCl, 0.2 μM ZnCl2, pH 7.5) at 37°C. Gels were briefly
washed and stained (1 g Coomassie blue, 200 mL metha-
nol, 50 mL acetic acid, 250 mL H2O) for 1 h at RT on
a rocker, followed by destaining in destaining buffer
(200 mL methanol, 50 mL acetic acid, 250 mL H2O) until
bands were clearly visible. Gels were scanned for densito-
metry analysis by ImageJ software (Wayne Rasband,
National Institutes of Health, Bethesda, MD, USA). As
MMP-2 is constitutively expressed and thus not regu-
lated, its band served as an internal loading control for
normalisation of densitometric data on MMP-9.
Cell viability assay
A 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazo-
lio]-1,3-benzene disulfonate (WST) assay was used to
measure cell viability. Therefore the cells were seeded
in 96-well plates. After treatment with or without
TNF-a [10 ng/mL] for 3 h, cells were treated with 6.25
μM SFN for a further 6 h. After the stimulation, the
media were supplemented with 10 μL/well (96-well
plate) WST 2 h before spectrophotometric evaluation.
Conversion of WST to formazan was measured at 450
nm by microplate spectrophotometry (Tecan Sunrise™,
Männedorf, Switzerland). This reaction reflects the
reductive capacity of the cells, thereby representing the
viability.
Cytotoxicity assay
CytoTox-Glo™ cytotoxicity assay (Promega, Madison,
WI, USA) was used to measure cytotoxicity. Cells were
seeded in 96-well plates and after treatment with or
without TNF-a [10 ng/mL] for 3 h, cells were treated
with 6.25 μM SFN for a further 6 h. A CytoTox-Glo™
cytotoxicity kit was used according to the manufac-
turer’s recommendation. Luminescence was measured in
a 96-well plate reader (GloMax™ 96 microplate lumin-
ometer; Promega, Madison, WI, USA).
Quantification of caspase activities
For measurements of caspase 3 and 7 activity, the Cas-
pase-Glo™ 3/7 assay (Promega, Madison, WI, USA) was
carried out according to the manufacturer’s instructions.
Cells were treated as described for the WST and Cyto-
Tox-Glo™ assay. This assay is based on the cleavage of
the DEVD sequence of a luminogenic substrate by cas-
pases 3 and 7, which results in a luminescent signal.
Real-time cell analysis (RTCA)
We analysed the effect of Nrf2 and TNF-a on prolifera-
tion of HSE cells by continuous real-time impedance
measurements using the xCELLigence system (Roche
Diagnostics, Mannheim, Germany). The xCELLigence
system contains a 96-well cell culture plate with a micro-
electrode array in the bottom of each well (E-Plate). The
electrode impedance of the separate wells can be mea-
sured in defined intervals and is finally converted to a
dimensionless parameter named Cell Index (CI). The CI
is zero without cell adherence and increases when cells
attach or proliferate on the microelectrode surface.
To measure the background impedance all wells of the
E-Plate were filled with 200 μL of growth medium. After-
wards 5.0 × 103 HSE cells stably expressing a shRNA tar-
geting Keap1 or a non-targeting control shRNA were
seeded by replacing 100 μL of the total medium per well.
Subsequently, impedance measurements were conducted
at intervals of 20 min under normal cell culture condi-
tions (37°C in a humidified 5% CO2 atmosphere). After
an overnight adherence phase, TNF-a was added to the
respective wells in a final concentration of 10 ng/mL by
replacing 100 μL medium per well, whereas control cells
received equal amounts of fresh medium. Impedance
measurements were continued then for additional 24 h.
Afterwards the CI was normalised to the time-point of
TNF-a addition and analysed using the RTCA software
version 1.2.1 (Roche Diagnostics). All measurements
were conducted with eight replicates.
Results
SFN blocked TNF-a-induced NF-B and AP-1 activation in
synoviocytes
To analyse the NF-B and AP-1 activation in vitro, we
established a dual luciferase reporter gene assay utilising
the cis-acting elements of NF-B and AP-1. Synovio-
cytes (K4IM) were pre-treated for 30 min with increas-
ing concentrations of SFN or solvent (0.25% DMSO) as
control and stimulated with 10 ng/mL TNF-a for 6 h.
Stimulation with TNF-a activated the NF-B-depen-
dent luciferase gene expression 7-fold compared to the
control. Pre-incubation with 0.5 μM SFN nearly halved
the TNF-a-induced activation to 3-fold over control.
Doubling the SFN concentration further halved the
TNF-a-induced activation to 1.5-fold and pre-incuba-
tion with 2.5 μM SFN completely restrained the TNF-a-
induced activation (Figure 1A).
Nearly the same effect of SFN could be seen with the
cis-acting element of AP-1. The TNF-a-induced 6-fold
induction of AP-1-dependent luciferase gene expres-
sion was reduced to 3.5-fold by pre-incubation with
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0.5 μM SFN. Incubation with 1 μM SFN further
reduced the activation to 2.5-fold. TNF-a-induced AP-
1 activation was also completely blocked by 2.5 μM
SFN (Figure 1B).
SFN inhibited the production of proinflammatory
cytokines in synoviocytes
We examined the effect of SFN on TNF-a-induced IL-
1b and IL-6 secretion. Synoviocytes (K4IM) were stimu-
lated with 10 ng/mL TNF-a for 24 h in the presence of
0, 0.5, 1.0, and 2.5 μM SFN and the concentration of
IL-1b and IL-6 in the supernatant was measured via
ELISA. SFN inhibited the TNF-a-induced release of IL-
1b and IL-6 in a concentration-dependent manner and
this effect was already significant at the lowest tested
concentration of 0.5 μM (Figure 2A and 2B).
SFN altered neither MMP secretion nor activity
One feature of RA is an overexpression and persistent
activity of MMPs whereby the extracellular matrix
(ECM) is destructed. We therefore studied the effect of
SFN on MMP-3/9 in our model of pannus formation.
TNF-a treatment significantly upregulated MMP-3/9
secretion and MMP-9 activity in cultured synoviocytes.
MMP-3/9 secretion at low SFN concentration showed a
trend of downregulation, which did not reach signifi-
cance in our model (Figure 3A and 3B). However, a
high concentration of 15 μM SFN significantly reduced
the MMP-9 activity in this experimental design, prob-
ably due to toxicity (Figure 3C and 3D).
SFN induced apoptosis in TNF-a-stimulated synoviocytes
We used WST to study the molecular mechanism by
which SFN inhibits the proliferation of synoviocytes. Cyto-
Tox-Glo and Caspase-Glo assays (Promega) were used to
analyse the effects of SFN on cell toxicity and apoptosis.
The results demonstrate that neither TNF-a nor SFN
treatment alone had any cytotoxic effects compared to
untreated control cells (Figure 4B, second and fourth col-
umn). In contrast, the treatment with TNF-a or SFN
alone led to an increased cell viability (Figure 4A, second
and fourth column). Indeed, 6.25 μM SFN had a cytotoxic
effect on TNF-a pre-treated but not on untreated cells
(Figure 4B, third column). The caspase enzyme activity
assay confirmed these findings. These results demonstrate
that there were no effects due to single administration of
TNF-a or SFN. However, a significant increase of caspase-
3/7 activity was found after 6.25 μM SFN stimulation of
TNF-a pre-treated cells (Figure 4C, third column).
Nrf2/ARE-activity is crucial for the differential effects of
the treatments
In order to investigate the effects of these treatments on
Nrf2/ARE activity, we carried out a dual luciferase
reporter gene assay with the ARE sequence of the rat
NQO1 gene. We were able to show that SFN induces
Nrf2/ARE activity (Figure 5A, fourth column), in contrast
to TNF-a, which caused no difference in ARE-driven
luminescence compared to untreated cells (Figure 5A,
second column). Co-stimulation of TNF-a pre-treated
synoviocytes seemed to further increase the SFN-
mediated Nrf2/ARE activation (Figure 5A, third column),
but analysis of the raw luminescence signals of the ARE-
regulated firefly luciferase and the internal control Renilla
luciferase revealed a TNF-a-dependent decrease in lumi-
nescence intensities in co-stimulated cells (Figure 5B and
5C, third column). There is evidence that the supposed
increased ratio of co-stimulated cells is based on a
decreased Renilla-mediated luminescence signal, result-
ing from a decreased amount of vital cells. DMSO, used
as vehicle in a concentration of 0.25%, showed no signifi-
cant effect on ARE activation (data not shown). We
further aimed to examine whether Nrf2/ARE activation
has an effect on growth and proliferation processes inde-
pendent of the effects of SFN application. We also
intended to investigate to which extent the Nrf2/ARE
activity might be responsible for the observed effects on
co-treated cells. Therefore, we stably transduced HSE
cells with the pLKO.1 vector containing a shRNA target-
ing Keap1 (the inhibitor of Nrf2) to achieve an increased
Nrf2 expression and activation, and performed a real-
time analysis of cell proliferation. TNF-a stimulation
initially showed no difference in proliferation between
the experimental groups (Figure 5D and 5F, Phase 1).
Comparing the untreated shKeap1 cell line with the
untreated shNonTarget cells over the whole time, we
only found a minor difference in terms of cell growth
and proliferation. TNF-a treatment of shNonTarget cells
resulted in increased proliferation compared to the
untreated shNonTarget cells (Figure 5D, Phase 3), as
indicated by a higher cell index (Figure 5E, TP 3 first and
second column) and an increased proliferation rate (Figure
5F, TP 3 first and second column) after 24 h of stimulation
time. The same TNF-a treatment showed the opposite
effect in shKeap1 cells (Figure 5D und 5F, Phase 2). These
cells exhibited a clearly decreased cell index (Figure 5E,
TP 3 first column) and showed a lower proliferation rate
already after 10 h of stimulation with no recovery from
this state during the entire experiment.
Discussion
Recently, we showed that oxidative stress is significantly
involved in cartilage degradation in experimental arthri-
tis and that Nrf2 activity is a major requirement for lim-
iting cartilage destruction [8]. Other detrimental factors
are unbounded inflammation and rampantly growing
pannus, invading cartilage and bone. The data suggest
that the proinflammatory transcription factors NF-B
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and AP-1 mediate pannus formation via induction of
synoviocyte proliferation and resistance against apopto-
sis [17].
The objective of this study was to find substances that
activate Nrf2 to protect cartilage tissue from oxidative
stress on the one hand and to inhibit the proinflammatory
transcription factors NF-B and AP-1 in order to attenu-
ate inflammation and pannus progression on the other
hand. Beside inflammatory processes, pannus formation is
a main feature of RA [18]. Therefore, we used TNF-a-sti-
mulated synoviocytes to model synovial hyperplasia as
part of pannus formation with rampantly growing and
cytokine producing cells.
Here we tested the anti-rheumatic potential of SFN in
vitro. First data showed that SFN has anti-arthritic and
immune regulatory effects in an in vitro and in vivo
model of RA [19]. In addition, it has been shown that
SFN induces apoptosis in cancer cells, and that it inhi-
bits the cell cycle, angiogenesis and inflammation [6,20].
Contrary to that, SFN is also known to efficiently acti-
vate Nrf2 and thereby protect cells against oxidative
damage [21]. Interestingly, in this context, loss of Nrf2
lead to significantly more cartilage damage in an in vivo
model of RA [8]. Until now, no explanation for these
differential effects of SFN on cells is described.
First, we investigated the expression level of the proin-
flammatory cytokine IL-1b in our model. TNF-a stimula-
tion upregulated the secretion of IL-1b in the cell culture
supernatant. Incubation with SFN markedly reduced this
cytokine upregulation in a dose-dependent manner
(Figure 2A). This may be a consequence of the reduced
activation of the proinflammatory transcription factors
NF-B and AP-1 due to SFN treatment (Figure 1A
and 1B).
Recently, we described IL-6 as a target gene of Nrf2
and SFN stimulation as an inductor of IL-6 expression
in hepatocytes [22]. In synoviocytes, SFN failed to upre-
gulate IL-6 (data not shown) and, in contrast, it signifi-
cantly inhibited TNF-a-induced IL-6 upregulation
(Figure 2B). However, the molecular mechanisms of
these opposing effects of Nrf2 regarding IL-6 expression
remain to be elucidated. Taken together, these data indi-
cate that SFN acts anti-inflammatory in our in vitro RA
model.
Besides cytokines, ECM-degrading matrix metallopro-
teinases (MMPs) are important in arthritis. MMPs are
mainly regulated by an AP-1 and NF-B promoter bind-
ing motif [23]. We therefore investigated the secretion
levels of MMP-3 and -9 and the activity state of MMP-9
in our in vitro model of RA. We showed that TNF-a
induces the secretion of MMP-3/9 as well as the activity
of MMP-9. Although, co-treatment with SFN could
neither downregulate the expression level of MMP-3
nor MMP-9 (Figure 3A-D).
There are several lines of evidence suggesting that cell
cycle progression and transcription factor activation of
synovial cells is altered towards a transformed ‘tumour-
like’ manner in RA [17]. It has been demonstrated that
activation of NF-B and AP-1 protects cells in the syno-
vium against apoptosis and provides a link between
inflammation and hyperplasia. This gave first evidence
that inhibition of NF-B and AP-1 reduces viability and
proliferation of inflamed synovial fibroblasts [17,24-27].
Based on this, we hypothesised that NF-B and AP-1
activation is vital for cytokine-activated synoviocytes and,
as a consequence, deactivation or inhibition of these fac-
tors via SFN results in cell death. First, we studied the
effect of TNF-a stimulation on cultured synoviocytes. As
described, TNF-a stimulation led to NF-B and AP-1
activation (Figure 1) and cells reacted with enhanced
cytokine production (Figure 2). SFN totally blocked the
TNF-a-induced transformation of synoviocytes and,
moreover, induced caspase activation (Figure 4C) and
cell death (Figure 4A and 4B). In contrast, SFN treatment
of naïve - not TNF-a-stimulated - synoviocytes resulted
in Nrf2 activation (Figure 5A-C) and upregulation of
cytoprotective enzymes such as HO-1, NQO1, thioredox-
ins and thioredoxin reductases. Furthermore, we were
able to show that not only the SFN-mediated NF-B
inhibition but also a SFN-independent Nrf2 activation
led to the same effect of decreasing cell viability, as in co-
stimulated wild-type cells in the previous experiments.
The RTCA experiments clearly revealed a Nrf2-driven
decrease of proliferation in response to TNF-a in HSE
cells stably transduced with shRNA directed against
Keap1 (the inhibitor of Nrf2). It was already shown that
Nrf2 activation leads to an upregulation of heme oxyge-
nase-1 (HO-1) [28]. Heme oxygenase-1 produces carbon
monoxide, which is described to efficiently inhibit NF-B
activity [29,30]. Hence, we suggest that the genetically
increased Nrf2 activity via Keap1 silencing and the resul-
tant HO-1-mediated CO production cause a similar inhi-
bition of NF-B as SFN does, leading to the same
impaired outcome in cell viability and proliferation. The
RTCA experiment emphasises that the observed effects
of SFN on TNF-a pre-treated cells may not only be
explained by direct inhibition of NF-B but also by SFN-
driven induction of Nrf2 activity, which indirectly inhibits
NF-B via HO-1-mediated CO production.
Conclusions
These data give first evidence that SFN selectively harms
‘transformed’ synoviocytes but vitalises naïve ‘untrans-
formed’ synoviocytes. Thus, since we have shown that
Nrf2 deficiency results in exacerbated cartilage destruc-
tion, Nrf2 activation via SFN may protect healthy syno-
viocytes and may lead to improved cartilage regeneration.
Due to the fact that the data is based on experiments
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done with immortalised cell lines, there is importance to
validate these results with primary fibroblast-like syno-
viocytes (FLS) cultures.
Our results demonstrate that SFN has anti-phlogistic
properties and may retard pannus formation. Moreover,
SFN activates the cell protective transcription factor
Nrf2 and may prevent cartilage destruction in RA.
These findings indicate that treatment of RA patients
with SFN might be considered as a novel therapeutic
strategy to combat joint destruction and inflammation
in RA.
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